Read Dr. Louise Moyle’s Early Career Blog
Read the latest early career blog post, from NMD4C member Dr. Louise Moyle.
Dr. Louise Moyle is a postdoctoral fellow at the Institute of Biomedical Engineering at the University of Toronto, Canada. Her research investigates mechanisms of muscle stem cell dysfunction in neuromuscular disorders, with the aim of transferring this knowledge towards future cell and gene therapies. She completed her PhD in Dr. Peter Zammit’s lab at King’s College London (UK), where she investigated muscle stem cell regeneration in facioscapulohumeral muscular dystrophy (FSHD). She is currently working in the laboratory of Dr. Penney Gilbert, where she is supported by a Medicine by Design postdoctoral fellowship. This research aims to understand how mechanosensing via the LINC complex contributes to the process muscle stem cell repair, with relevance to Emery-Dreifuss muscular dystrophy.
Read next...
Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG
Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!
2026 Awards Now Open for Nominations!
We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.